Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma
Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma have?
Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma has 60 citations in the OpenAlex counts ScholarIQ stores.
When was Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma published?
Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma has 2016 year in the ScholarIQ index.
What is the open-access status of Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma?
Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma has green oa status in the ScholarIQ index.
What is the DOI of Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma?
The DOI for Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma is on the source record.
What is the PMID of Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma?
The PMID for Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma is on the source record.
What is the OpenAlex record for Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma?
The OpenAlex for Phase <scp>II</scp> study of dual phosphoinositol‐3‐kinase ( <scp>PI</scp> 3K) and mammalian target of rapamycin ( <scp>mTOR</scp> ) inhibitor <scp>BEZ</scp> 235 in patients with locally advanced or metastatic transitional cell carcinoma is on the source record.